Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Acosta

Showing results (211-220 of 338) with videos related to

Pageof 34
Sort By:
HIV Clinical Trials|July 28, 2009
Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adultsLeigh Anne Redhage, Ayumi Shintani, David W Haas, et al.
Clinical and Diagnostic Laboratory Immunology|July 11, 2003
Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoproteinTetsuro Ikegami, Masahiro Niikura, Masayuki Saijo, et al.
Plos Neglected Tropical Diseases|October 23, 2009
Anemia of inflammation is related to cognitive impairment among children in Leyte, the PhilippinesCourtney L Olson, Luz P Acosta, Natasha S Hochberg, et al.
AIDS (London, England)|July 11, 2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapineJeffrey S A Stringer, Moses Sinkala, Victoria Chapman, et al.
The Journal of Infectious Diseases|August 6, 2004
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjectsRonald Swanstrom, Ronald J Bosch, David Katzenstein, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot studyBabafemi Taiwo, Edward P Acosta, Patrick Ryscavage, et al.
Nature Medicine|June 17, 2008
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsLin Shen, Susan Peterson, Ahmad R Sedaghat, et al.
The Pediatric Infectious Disease Journal|September 2, 2016
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young AdultsTim R Cressey, Rohan Hazra, Andrew Wiznia, et al.
AIDS (London, England)|January 11, 2000
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884C V Fletcher, E P Acosta, H Cheng, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 4, 2006
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherenceHulin Wu, Yangxin Huang, Edward P Acosta, et al.
Pageof 34

Showing results (211-220 of 338) with videos related to

Sort By:
Pageof 34
HIV Clinical Trials|July 28, 2009
Clinical factors associated with plasma F2-isoprostane levels in HIV-infected adultsLeigh Anne Redhage, Ayumi Shintani, David W Haas, et al.
Clinical and Diagnostic Laboratory Immunology|July 11, 2003
Antigen capture enzyme-linked immunosorbent assay for specific detection of Reston Ebola virus nucleoproteinTetsuro Ikegami, Masahiro Niikura, Masayuki Saijo, et al.
Plos Neglected Tropical Diseases|October 23, 2009
Anemia of inflammation is related to cognitive impairment among children in Leyte, the PhilippinesCourtney L Olson, Luz P Acosta, Natasha S Hochberg, et al.
AIDS (London, England)|July 11, 2003
Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapineJeffrey S A Stringer, Moses Sinkala, Victoria Chapman, et al.
The Journal of Infectious Diseases|August 6, 2004
Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjectsRonald Swanstrom, Ronald J Bosch, David Katzenstein, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 26, 2013
Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot studyBabafemi Taiwo, Edward P Acosta, Patrick Ryscavage, et al.
Nature Medicine|June 17, 2008
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsLin Shen, Susan Peterson, Ahmad R Sedaghat, et al.
The Pediatric Infectious Disease Journal|September 2, 2016
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young AdultsTim R Cressey, Rohan Hazra, Andrew Wiznia, et al.
AIDS (London, England)|January 11, 2000
Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV- infected subjects: ACTG 884C V Fletcher, E P Acosta, H Cheng, et al.
Journal of Pharmacokinetics and Pharmacodynamics|April 4, 2006
Pharmacodynamics of antiretroviral agents in HIV-1 infected patients: using viral dynamic models that incorporate drug susceptibility and adherenceHulin Wu, Yangxin Huang, Edward P Acosta, et al.
Pageof 34